Antibodies as Drugs joint with Cancer Immunology and Immunotherapy Organizer(s): Paul Carter and Andreas G. Plückthun Date: January 27 - February 01, 2013
Location: Fairmont Hotel Vancouver, Vancouver, BC, CanadaAntibodies have come of age as therapeutics since the late 1990s with 26 antibody therapeutics marketed in the USA and approximately 300 additional antibodies in clinical development. Many of these antibody drugs are targeted to malignant cells and are used for the treatment of a variety of cancers. Participants at this meeting will consider new therapeutic opportunities for antibodies and engineered targeting molecules across a broad range of clinical settings including oncology, autoimmunity and chronic inflammation, infectious diseases and neurology. Progress in molecular engineering to increase their clinical potential will be discussed including antibody-drug conjugates, bispecific and multispecific targeting molecules, effector function enhancement and half-life extension. New frontiers will be explored including engineering antibodies to cross the blood-brain barrier and tackling fundamental questions in antibody targeting, mechanisms of action and resistance, and immunogenicity of engineered proteins. This symposium will bring together experts from academia and industry, from molecular engineering to biomedical applications, at the forefront of advancing antibodies as drugs and will be of broad interest to scientists working in this area. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Cancer Immunology and Immunotherapy, which will share two plenary sessions with this meeting. Scholarship Deadline: September 25 2012 Discounted Abstract Deadline: September 25 2012 Abstract Deadline: October 25 2012 Discounted Registration Deadline: November 27 2012 We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Genentech, Inc.
Micromet, Inc.
MedImmune
|